ATS 2022
TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Your search for oral corticosteroids returned 14 results
CHEST 2022
Dupilumab Reduces Oral Corticosteroid Use in OCS-Dependent Severe Asthma
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
CHEST 2022
ICS-LABA Proved Effective in Treating Sjogren Syndrome With Bronchiolitis
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
AAAAI 2022
Escalation to Biologics in Asthma: The Role of Suboptimal Treatment Adherence
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
AAAAI 2022
Azithromycin and Recurrent Wheeze in Children After Severe RSV Bronchiolitis
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
CHEST 2022
Tezepelumab Improves Severe Asthma Even in Those Using Multiple Controllers
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
CHEST 2022
Tezepelumab Improves Severe Asthma Even in Those Using Multiple Controllers
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
ATS Virtual Program 2020
Low-Severity COPD: Risk for Exacerbation, Hospitalization, and Death
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
CHEST 2022, News
Switching or Stopping Biologic Therapy in Severe Asthma Yields Worse Outcomes
The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.
News
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
